Why Cost Of Delivery, Not Rate, Is The Lever CROs Actually Control

Functional service outsourcing (FSO) and unitized FSP CROs are operating in a market that looks very different than it did just a few years ago. Tighter funding, increasing pressure from smaller and more cost-conscious sponsors, looming patent expirations, and growing expectations around AI are reshaping the economics of clinical development. For organizations whose business models rely on resource-based rate cards, the challenge is no longer simply negotiating rates, it is reducing the cost of delivery.

This thought leadership piece explores why traditional approaches to staffing and utilization are reaching their limits and examines where the next wave of operational efficiency is likely to emerge. With clinical monitoring representing a significant portion of trial costs, AI-enabled workflows offer a path to increased productivity, stronger quality outcomes, and improved margins without proportional headcount growth.

Learn how leading CROs can rethink their operating models, capitalize on productivity gains, and position themselves for success as industry economics continue to evolve.